United Therapeutics Chairperson & CEO Martine Rothblatt Exercises Options and Sells $5.16M via 10b5-1 Plan

Executive Summary

On October 19, 2026, Dr. Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp (UTHR), exercised 9,500 stock options at an exercise price of $117.76 per share and concurrently sold the underlying 9,500 shares of common stock at a weighted average price of approximately $543.32, generating gross sale proceeds of approximately $5.16 million.

Transaction Details

• Nature of Trade: The transactions were conducted pursuant to a pre-arranged Rule 10b5-1 trading plan established on November 7, 2025.
• Derivative Exercise: 9,500 stock options expiring on March 15, 2027, were exercised at $117.76 each.
• Sales: Shares were disposed of through 19 separate tranches at weighted average prices ranging from $534.75 to $556.88.
• Holdings After Transaction: Following the transactions, Dr. Rothblatt indirectly holds 324,443 shares through the executing trust, alongside hundreds of thousands of additional shares held across other family trusts and directly (40,513 direct shares).

Market & Significance Assessment

Because this transaction represents a standard exercise-and-sell under a pre-established Rule 10b5-1 trading plan adopted nearly a year prior, it does not reflect discretionary, opportunistic selling or a shift in executive sentiment. As such, the trading significance is rated Low.